The consensus by late 2021 has hardened: tirzepatide is a sure thing. The single fact that should temper that is the status word in Lilly's own filing — “Submitted.” Not approved. Submitted.
Lilly's Form 10-Q filed October 27, 2021 lists tirzepatide for type 2 diabetes as Submitted, noting the company announced in the first and second quarters of 2021 that it had filed for regulatory review. That is a real milestone — a regulatory submission is the company saying it believes its data package is complete. But a submission is an application, not a verdict. The agency can still ask for more, narrow the label, or delay.
Read the risk factors and the obesity story is even earlier. The same filing trail shows the obesity program still in Phase III as of 2021 — meaning the indication that drives the biggest revenue fantasies is not yet even submitted. The Street is conflating an approved diabetes drug, a submitted diabetes drug, and an in-trial obesity drug into one inevitable franchise. The filing keeps those three things separate, because legally it has to.
Acknowledge the bull case honestly: “Submitted” is a strong signal, and Lilly does not file lightly. But the gap between submission and the market's enthusiasm is exactly the kind of gap that costs money when timelines slip. The 10-Q is a status report, and the status is pending.
The contrarian point is not that tirzepatide will fail — it is that the certainty in the narrative is not yet in the documents. A reader who treats “Submitted” as “approved” is reading a press cycle, not a filing.
The EdgarBeast evidence index, which surfaces and normalizes SEC filings, makes the distinction concrete by letting you watch a candidate's status word change over time. As of late 2021, the word is “Submitted” for diabetes and “Phase III” for obesity. That is the record.